Please assess the completion status of the following clinical trial:

Trial Title: MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Diagnosis of MS according to McDonald criteria.~* Current muscle stiffness ≥ 4 on a 11-point categorical rating scale.~* On-going troublesome muscle stiffness for at least 3 months.~* Stable disease for the previous 6 months.~* Antispasticity medication and physiotherapy stabilised for the last 30 days.~* Patients may be ambulatory or not.~* Age 18-64.~Exclusion Criteria:~* Immunosuppressants which may affect spasticity (including corticosteroids and interferon but ex-cluding azathioprine) taken currently or in previous 30 days~* Past or present history of psychotic illness.~* Open/infected pressure sores or other source of chronic infection.~* Significant fixed tendon contractures.~* Severe cognitive impairment such that the patient is unable to provide informed consent.~* History of clinically important renal, cardiovascular or neurol. diseases (apart from MS).~* Malignancy within the past 2 years.~* Cannabinoids taken currently or in previous 30 days.~* Positive qualitative urinary test on cannabinoids at screening visit. (In this case a patient will be allowed to repeat the test at a second screening visit later.)~* Known hypersensitivity to cannabinoids.~* Current drug abuse, including alcohol abuse.~* Laboratory parameters outside the following limits:~Creatinine \> 3x upper limit of normal Bilirubine \> 3x upper limit of normal Transaminases \> 5 x upper limit of normal~* Anticipated immunisations within the 12 weeks of trial participation.~* Other problems likely to make participation difficult at the discretion of the neurologist.~* Women who are pregnant, lactating or not using adequate contraception.~* Participation in other treatment studies currently or within the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
- 2 (Type: PLACEBO_COMPARATOR): matching placebo capsules, twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).